N/A N=445 Symptom Screening Linked to Care Pathways
Pediatric Cancer · Quality of Life
Primary: Symptom Screening in Pediatrics Tool (SSPedi) Total Score — 7.9; 11.4 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
Other Cancer
Primary: Percentage of Participants Recruited — 20; 20 Participants
Phase 2 N=100 Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
N/A N=70 Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Non-rhabdomyosarcoma Soft Tissue Sarcoma · Bone Sarcoma
Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants
N/A N=23 Massage for Pediatric Oncology
Bone Marrow Transplantation · Distress
Primary: Number of Days With Pain Scores >3 Measured on Numeric Rating Scale (Range 0-10; 0 for no Pain; 10 for Worst Pain Imaginable) — 7.7; 8.3 days — p=0.80
Phase 2 N=72 A Study of Pemetrexed in Children With Recurrent Cancer
Osteosarcoma · Medulloblastoma · Sarcoma, Ewing's
Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
N/A N=115 Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma
Rhabdomyosarcoma
Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients
Phase 2 N=47 Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
N/A N=347 Communicating Health Information and Improving Coordination With Primary Care
Hypertension · Dyslipidemias · Diabetes
Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…
Phase 2 N=106 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Leukemia, Pediatric
Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
N/A N=116 Pediatric Guideline Adherence and Outcomes- Argentina
TBI (Traumatic Brain Injury)
Primary: First 3-day Cumulative Intensive Care Unit (ICU) Traumatic Brain Injury (TBI) Guideline Adherence Rate, Overall — 81.7; 81.0; 83.7; 84.4 mean percentage of guideline…
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=13 Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
N/A N=167 Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Burkitt Lymphoma · Retinoblastoma · Diffuse Large B-cell Lymphoma
Primary: Protocol Compliance as Measured by Percent Compliance to Prescribed Chemotherapy — 73.8; 96.0; 50.0; 74.9 percentage of compliance — p=<0.001
Phase 2 N=23 Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
N/A N=52 Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
Neuroblastoma · Medulloblastoma · Brain Tumors
Primary: Determine Feasibility Using Days From the Date of Biopsy to Date of Start of Treatment — 12.2; 19.9; 14.9 Days
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Phase 4 N=156 Vaccinating Children After Chemotherapy
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Phase 2 N=38 Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Venous Thromboembolism
Primary: Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level — 125 IU/mL
Phase 1 N=68 A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Neoplasm Metastasis
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
N/A N=31 Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors
Cancer Survivor
Primary: Feasibility as Measured by Study Enrollment Rates, Retention Rates, Adherence to the Intervention, and Reasons for Study Drop Out. — 20; 11; 8; 0 Participants
Phase 2 N=34 Antineoplaston Therapy in Treating Children With Brain Tumors
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Phase 3 N=43 CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants